Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Key Inclusion Criteria: * Part A: histologically or cytologically confirmed advanced malignant solid tumor that is refractory to or intolerant of standard therapy or for which no standard therapy is available * Part B: Pancreatic Adenocarcinoma * Presence of histologically confirmed inoperable locally advanced or metastatic pancreatic adenocarcinoma * Part B: NSCLC * Stage IIIB with malignant pleural effusion/pleural seeding or stage IV histologically confirmed NSCLC * Absence of known epidermal growth factor receptor (EGFR) mutation * Absence of known translocation or inversion events involving the ALK gene locus (resulting in EML4-ALK fusion) * Part B: Esophagogastric Adenocarcinoma: * Histologically confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapsed gastric adenocarcinoma * Human epidermal growth factor receptor 2 (HER2)-negative tumor (primary tumor or metastatic lesion) * Part B: First-Line Colorectal Cancer * Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum * Radiographically measureable disease * No prior cytotoxic chemotherapy to treat their metastatic disease * Part B: Second-Line Colorectal Cancer * Histologically confirmed inoperable advanced adenocarcinoma of the colon or rectum * Radiographically measureable disease * Received first-line combination therapy containing oxaliplatin and fluoropyrimidine with or without bevacizumab for metastatic disease with documented evidence of disease progression during or after treatment completion * Part B: Breast Cancer * Histologically or cytologically confirmed metastatic breast cancer * Radiographically measureable disease * Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed * Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician * HER-2 negative tumor (primary tumor or metastatic lesion) * Adequate organ function Key Exclusion Criteria: * Pregnant or lactating * Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic steroids * Myocardial infarction, symptomatic congestive heart failure, unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months * Anti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted Note: Other protocol defined Inclusion/Exclusion criteria may apply.